Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Valuation & Earnings
This table compares Qualigen Therapeutics and VYNE Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Qualigen Therapeutics | N/A | N/A | -$6.26 million | ($7.50) | -0.17 |
| VYNE Therapeutics | $500,000.00 | 39.60 | -$39.83 million | ($0.78) | -0.76 |
Volatility and Risk
Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.
Institutional & Insider Ownership
3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Qualigen Therapeutics and VYNE Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qualigen Therapeutics | N/A | N/A | -202.16% |
| VYNE Therapeutics | -6,425.19% | -80.84% | -66.20% |
Analyst Ratings
This is a breakdown of current ratings for Qualigen Therapeutics and VYNE Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
VYNE Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 656.56%. Given VYNE Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe VYNE Therapeutics is more favorable than Qualigen Therapeutics.
Summary
VYNE Therapeutics beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
